Referencias

1. Página web del Instituto Nacional del Cáncer. En: http://www.cancer.gov
2. Página web de la Cancer Network (Red del Cáncer). En: http://www.cancernetwork.com
3. Página web de la Sociedad Americana del Cáncer. En: http://www.cancer.org
4. Brichard VG, Lejeune D. GSK’s Antigen-Specific Cancer Immunotherapy Programme: Pilot results leading to Phase III clinical development. Vaccine. 2007 25(Suppl 2):B61-71.
5. Mitchell M. Cancer vaccines, a critical review - Part I. Current Opinion in Investigational Drugs. 2002 3(1):140-9.
6. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Current Opinion in Immunology. 1997; 9:684-93.
7. Vansteenkiste, J, Zielinski, M, Linder, A. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC). 43rd ASCO Annual Meeting Chicago USA, 1-5 de junio de 2007.
8. Nota descriptiva nº 297 2006 de la OMS en: http://www.who.int/mediacentre/factsheets/fs297/es/index.html
9. Parkin DM D.M. Parkin The Lancet Oncology 2: 533-543 (2001)